Esperion Therapeutics Inc (ESPR) — Net Asset Quality Index
Esperion Therapeutics Inc (ESPR) has a Net Asset Quality Index of -124.0% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $364.02 Million minus total liabilities of $815.38 Million yields net assets of $-451.36 Million. A higher index indicates a stronger, lower-leverage balance sheet. See ESPR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Esperion Therapeutics Inc Net Asset Quality Index Over Time (1999–2024)
This chart shows how Esperion Therapeutics Inc's Net Asset Quality Index has evolved across 18 annual periods from 1999 to 2024. As of September 2025, the index stands at -124.0%, representing net assets of $-451.36 Million against total assets of $364.02 Million USD. Explore cash efficiency ratio of Esperion Therapeutics Inc to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Esperion Therapeutics Inc (1999–2024)
The table below presents the year-by-year Net Asset Quality Index for Esperion Therapeutics Inc from 1999 to 2024, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see ESPR market cap.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | -113.1% | $-388.72 Million | $343.82 Million | $732.54 Million | ▲ +108.0 pp |
| 2023 | -221.1% | $-454.99 Million | $205.80 Million | $660.79 Million | ▼ -90.5 pp |
| 2022 | -130.6% | $-323.78 Million | $247.94 Million | $571.72 Million | ▼ -79.0 pp |
| 2021 | -51.6% | $-196.94 Million | $381.59 Million | $578.53 Million | ▼ -24.4 pp |
| 2020 | -27.2% | $-96.13 Million | $353.26 Million | $449.39 Million | ▼ -36.5 pp |
| 2019 | 9.3% | $19.95 Million | $214.45 Million | $194.50 Million | ▼ -45.9 pp |
| 2018 | 55.2% | $79.12 Million | $143.45 Million | $64.33 Million | ▼ -32.9 pp |
| 2017 | 88.1% | $244.69 Million | $277.83 Million | $33.14 Million | ▼ -5.2 pp |
| 2016 | 93.2% | $228.60 Million | $245.21 Million | $16.61 Million | ▼ -4.0 pp |
| 2015 | 97.2% | $287.26 Million | $295.57 Million | $8.31 Million | ▲ +4.0 pp |
| 2014 | 93.2% | $133.55 Million | $143.34 Million | $9.79 Million | ▼ -1.5 pp |
| 2013 | 94.6% | $74.09 Million | $78.29 Million | $4.20 Million | ▲ +332.4 pp |
| 2012 | -237.8% | $-17.39 Million | $7.31 Million | $24.70 Million | ▲ +40.1 pp |
| 2011 | -277.9% | $-6.06 Million | $2.18 Million | $8.24 Million | ▼ -353.2 pp |
| 2002 | 75.4% | $38.74 Million | $51.41 Million | $12.66 Million | ▼ -9.5 pp |
| 2001 | 84.9% | $66.50 Million | $78.34 Million | $11.84 Million | ▼ -2.0 pp |
| 2000 | 86.9% | $67.69 Million | $77.88 Million | $10.19 Million | ▲ +51.7 pp |
| 1999 | 35.2% | $2.81 Million | $8.00 Million | $5.18 Million | — |